Results 201 to 210 of about 169,027 (313)

The potential for therapeutic drug monitoring of belatacept and other biologicals in solid organ transplantation

British Journal of Clinical Pharmacology, EarlyView.
Abstract In solid organ transplantation (SOT), biologicals such as recombinant therapeutic proteins, monoclonal antibodies, fusion proteins and conjugates are increasingly used for immunosuppression, desensitization, ABO (blood group) incompatibility, antibody‐mediated rejections and atypical haemolytic uremic syndrome.
Stein Bergan, Nils Tore Vethe
wiley   +1 more source

The molecular landscape of AL amyloidosis

British Journal of Haematology, EarlyView.
Within the bone marrow, the clonal plasma cell population exhibits an abnormal expression of non‐coding RNAs, which, in turn, upregulates anti‐apoptotic genes (BCL2, MCL1, BCL2L1), leading to an anti‐apoptotic effect that promotes plasma cell survival.
Tal Zvida‐Bloch, Eli Muchtar, Angela Dispenzieri, Ofer Shpilberg, Oshrat Hershkovitz‐Rokah   +4 more
wiley   +1 more source

T-Cell-Dependent Bispecific IgGs Protect Aged Mice From Lethal SARS-CoV-2 Infection. [PDF]

Adv Sci (Weinh)
Fu W, Zhang W, You Z, Li G, Wang C, Lei C, Zhao J, Hou J, Hu S.   +8 more
europepmc   +1 more source

How we manage immune‐mediated thrombotic thrombocytopenic purpura after rituximab failure or intolerance

British Journal of Haematology, EarlyView.
The use of rituximab as a pre‐emptive treatment in immune‐mediated thrombotic thrombocytopenic purpura (iTTP) is the current standard of care. However, for patients refractory to rituximab or for those with contraindication, further treatment guidelines are scarce.
Julia Weisinger, Jehane Fadlallah, Bérangère Joly, Agnès Veyradier, Paul Coppo   +4 more
wiley   +1 more source

Engineering and characterization of Hu3A4: A novel humanized antibody with potential as a therapeutic agent against myeloid lineage leukemias. [PDF]

Neoplasia
Li S, Wang Z, Guo X, Tang Y.
europepmc   +1 more source

Atezolizumab, obinutuzumab and venetoclax for the treatment of patients with relapsed/refractory B non‐Hodgkin lymphoma: Final analysis of a phase II trial from the LYSA group

British Journal of Haematology, EarlyView.
Summary Developing new therapeutic regimens for relapsed/refractory (R/R) B non‐Hodgkin lymphoma (NHL) patients remains a significant unmet clinical need. Our objective was to evaluate atezolizumab (ATE), obinutuzumab (OBI) and venetoclax (VEN) combination in patients with R/R NHL who had received at least one prior anti‐CD20‐containing ...
Charles Herbaux, Emmanuel Bachy, Reda Bouabdallah, Stéphanie Guidez, Olivier Casasnovas, Pierre Feugier, Gandhi Damaj, Hervé Tilly, Loïc Ysebaert, Steven Le Gouill, Nadine Morineau, Emmanuel Gyan, Rémy Gressin, Roch Houot, Morgane Cheminant, Franck Morschhauser, Catherine Thieblemont, Corinne Haioun, Emmanuelle Nicolas‐Virelizier, Luc‐Matthieu Fornecker, Nicolas Daguindau, Guillaume Cartron   +21 more
wiley   +1 more source

Development of Antibody-Drug Conjugates for Malignancies of the Uterine Corpus: A Review. [PDF]

Cells
Yamanaka T, Nishikawa T, Yoshida H.
europepmc   +1 more source

The impact of Foxp3+ regulatory T‐cells on CD8+ T‐cell dysfunction in tumour microenvironments and responses to immune checkpoint inhibitors

British Journal of Pharmacology, EarlyView.
Immune checkpoint inhibitors (ICIs) have been a breakthrough in cancer therapy, inducing durable remissions in responding patients. However, they are associated with variable outcomes, spanning from disease hyperprogression to complete responses with the onset of immune‐related adverse events.
Mikhaël Attias, Ciriaco A. Piccirillo
wiley   +1 more source

Dual biological treatments in immune-mediated disorders: a single center experience. [PDF]

BMC Immunol
Shamriz O, Parnasa E, Rubin L, Talmon A, Ribak Y, Hindi I, Peleg H, Confino-Cohen R, Tal Y.   +8 more
europepmc   +1 more source

Treatment options for immune‐related adverse events associated with immune checkpoint inhibitors

British Journal of Pharmacology, EarlyView.
Abstract The immunotherapy revolution with the use of immune checkpoint inhibitors (ICIs) started with the clinical use of the first ICI, ipilimumab, in 2011. Since then, the field of ICI therapy has rapidly expanded — with the FDA approval of 10 different ICI drugs so far and their incorporation into the therapeutic regimens of a range of malignancies.
Yu Hua Chen, Tamás Kovács, Péter Ferdinandy, Zoltán V. Varga   +3 more
wiley   +1 more source